SCHEMBL20135595

SCHEMBL20135595

Cc1cc(C)c2c(C3CCN(C(=O)OC(C)(C)C)CC3)nn(C)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
KDM4E B2RXH2 2/20 0.46
THRB P10828 1/20 0.46
EPHX2 P34913 2/20 0.44
CNR1 P21554 1/20 0.44
GPR119 Q8TDV5 3/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
CRHBP P24387 1/20 0.42
HTT P42858 1/20 0.42
CRHR2 Q13324 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TP53 P04637 2/20 0.41
LMNA P02545 1/20 0.41
JAK2 O60674 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135481 0.82 KDM4E (0.45) MAPTKDM4ETHRBCNR1GPR119
SCHEMBL20135368 0.80 CNR1 (0.41) MAPTKDM4ETHRBEPHX2CNR1
SCHEMBL20135077 0.78 MAPT (0.52) MAPTKDM4ETHRBEPHX2GPR119
SCHEMBL31426765 0.76 CNR1 (0.50) MAPTKDM4ETHRBCNR1GPR119
SCHEMBL27141837 0.76 CNR1 (0.50) MAPTKDM4ETHRBCNR1GPR119
SCHEMBL29190562 0.75 DDB1 (0.54) MAPTKDM4ETHRBCNR1GPR119
SCHEMBL2958107 0.75 CNR1 (0.44) MAPTKDM4ETHRBCNR1GPR119
SCHEMBL15180524 0.74 TP53 (0.48) MAPTKDM4ETHRBEPHX2GPR119
SCHEMBL18685698 0.73 KDM4E (0.52) MAPTKDM4ETHRBGPR119KMT2A
SCHEMBL21085244 0.73 KDM4E (0.52) MAPTKDM4ETHRBEPHX2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MAPT 4505/4885KDM4E 725/4885THRB 4280/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MAPT 4265/4885KDM4E 723/4885THRB 4174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.